PDF(Pubmed)
Abstract：
UNASSIGNED: Inflammatory bowel disease is an incurable group of recurrent inflammatory diseases of the intestine. Mendelian randomization has been utilized in the development of drugs for disease treatment, including the therapeutic targets for IBD that are identified through drug-targeted MR.
UNASSIGNED: Two-sample MR was employed to explore the cause-and-effect relationship between multiple genes and IBD and its subtypes ulcerative colitis and Crohn\'s disease, and replication MR was utilized to validate this causality. Summary data-based Mendelian randomization analysis was performed to enhance the robustness of the outcomes, while Bayesian co-localization provided strong evidential support. Finally, the value of potential therapeutic target applications was determined by using the estimation of druggability.
UNASSIGNED: With our investigation, we identified target genes associated with the risk of IBD and its subtypes UC and CD. These include the genes GPBAR1, IL1RL1, PRKCB, and PNMT, which are associated with IBD risk, IL1RL1, with a protective effect against CD risk, and GPX1, GPBAR1, and PNMT, which are involved in UC risk.
UNASSIGNED: In a word, this study identified several potential therapeutic targets associated with the risk of IBD and its subtypes, offering new insights into the development of therapeutic agents for IBD.
UNASSIGNED: Two-sample MR was employed to explore the cause-and-effect relationship between multiple genes and IBD and its subtypes ulcerative colitis and Crohn\'s disease, and replication MR was utilized to validate this causality. Summary data-based Mendelian randomization analysis was performed to enhance the robustness of the outcomes, while Bayesian co-localization provided strong evidential support. Finally, the value of potential therapeutic target applications was determined by using the estimation of druggability.
UNASSIGNED: With our investigation, we identified target genes associated with the risk of IBD and its subtypes UC and CD. These include the genes GPBAR1, IL1RL1, PRKCB, and PNMT, which are associated with IBD risk, IL1RL1, with a protective effect against CD risk, and GPX1, GPBAR1, and PNMT, which are involved in UC risk.
UNASSIGNED: In a word, this study identified several potential therapeutic targets associated with the risk of IBD and its subtypes, offering new insights into the development of therapeutic agents for IBD.
摘要：
■炎症性肠病是一组无法治愈的肠道复发性炎症性疾病。孟德尔随机化已用于疾病治疗药物的开发，包括通过药物靶向MR鉴定的IBD治疗靶标。
■采用两个样本MR来探索多个基因与IBD及其亚型溃疡性结肠炎和克罗恩病之间的因果关系。复制MR被用来验证这种因果关系。进行基于汇总数据的孟德尔随机化分析以增强结果的稳健性，而贝叶斯共同本地化提供了强有力的证据支持。最后,潜在的治疗目标应用的价值是通过使用药物的估计来确定的.
■通过我们的调查，我们确定了与IBD及其亚型UC和CD风险相关的靶基因.这些基因包括GPBAR1，IL1RL1，PRKCB，和PNMT,与IBD风险相关，IL1RL1，对CD风险具有保护作用，以及GPX1、GPBAR1和PNMT，这与UC风险有关。
■总之,这项研究确定了几个与IBD及其亚型风险相关的潜在治疗靶点，为IBD治疗药物的开发提供新的见解。
■采用两个样本MR来探索多个基因与IBD及其亚型溃疡性结肠炎和克罗恩病之间的因果关系。复制MR被用来验证这种因果关系。进行基于汇总数据的孟德尔随机化分析以增强结果的稳健性，而贝叶斯共同本地化提供了强有力的证据支持。最后,潜在的治疗目标应用的价值是通过使用药物的估计来确定的.
■通过我们的调查，我们确定了与IBD及其亚型UC和CD风险相关的靶基因.这些基因包括GPBAR1，IL1RL1，PRKCB，和PNMT,与IBD风险相关，IL1RL1，对CD风险具有保护作用，以及GPX1、GPBAR1和PNMT，这与UC风险有关。
■总之,这项研究确定了几个与IBD及其亚型风险相关的潜在治疗靶点，为IBD治疗药物的开发提供新的见解。
